Zimmerman and colleagues examined how many depressed patients who scored in the remission range on the 17-item Hamilton Depression Rating Scale (HDRS) did not consider themselves to be in remission ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
Biohaven's Phase 2 study with BHV-7000 in MDD did not meet its primary endpoint of reducing depressive symptoms in comparison ...
Biohaven shares are flat after the company announced its Phase 2 proof-of-concept study of BHV-7000 failed to meet its ...
US clinical-stage biopharma Biohaven has reported disappointing results from a Phase II proof-of-concept study evaluating BHV ...
Biohaven’s phase 2 proof-of-concept study with BHV-7000 in major depressive disorder fails to meet its primary endpoint: New Haven, Connecticut Monday, December 29, 2025, 13:00 ...
Despite the disappointing primary results, Biohaven noted some positive trends in specific subgroups, particularly among patients with more severe depression at screening and baseline. The company ...
Dealing with mental health conditions like depression can be challenging. Some people struggle to find the right treatment or combination of treatments for their condition. In major depression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback